The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma
- PMID: 29163959
- PMCID: PMC5676553
- DOI: 10.1177/2050640617705576
The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma
Abstract
The gut microbiota has recently been recognized as a major environmental factor in the pathophysiology of many human diseases. The anatomical and function connection existing between gut and liver provides the theoretical basis to assume the liver is a major target for gut microbes. In the last decades, numerous studies reported an altered composition of gut microbiota in patients with liver cirrhosis and a progressively marked dysbiosis with worsening of the liver disease. The risk of developing hepatocellular carcinoma, the deadliest complication of liver cirrhosis, is widely variable among cirrhotic patients, thus suggesting a complexity of genetic and environmental factors implicated in hepatocarcinogenesis. Gut microbiota is now emerging as a plausible candidate to explain this variability. In this manuscript we review the human and the experimental evidence supporting the potential implication of gut microbiota in the promotion, progression and complication of liver disease.
Keywords: Gut bacteria; bacterial translocation; dysbiosis; liver carcinogenesis.
Similar articles
-
Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease.Clin Exp Hepatol. 2019 Mar;5(1):1-10. doi: 10.5114/ceh.2019.83151. Epub 2019 Feb 20. Clin Exp Hepatol. 2019. PMID: 30915401 Free PMC article. Review.
-
Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.World J Gastroenterol. 2016 Mar 14;22(10):2949-59. doi: 10.3748/wjg.v22.i10.2949. World J Gastroenterol. 2016. PMID: 26973391 Free PMC article.
-
Gut microbiota: A new piece in understanding hepatocarcinogenesis.Cancer Lett. 2020 Apr 1;474:15-22. doi: 10.1016/j.canlet.2020.01.002. Epub 2020 Jan 7. Cancer Lett. 2020. PMID: 31917160 Review.
-
Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.World J Gastroenterol. 2014 Dec 7;20(45):16795-810. doi: 10.3748/wjg.v20.i45.16795. World J Gastroenterol. 2014. PMID: 25492994 Free PMC article. Review.
-
Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?Diseases. 2019 Nov 12;7(4):58. doi: 10.3390/diseases7040058. Diseases. 2019. PMID: 31726747 Free PMC article. Review.
Cited by
-
Role of tenofovir dipivoxil in gut microbiota recovery from HBV-infection induced dysbiosis.BMC Microbiol. 2024 Sep 20;24(1):359. doi: 10.1186/s12866-024-03457-4. BMC Microbiol. 2024. PMID: 39304810 Free PMC article.
-
Unraveling the Microbiome-Human Body Axis: A Comprehensive Examination of Therapeutic Strategies, Interactions and Implications.Int J Mol Sci. 2024 May 20;25(10):5561. doi: 10.3390/ijms25105561. Int J Mol Sci. 2024. PMID: 38791599 Free PMC article. Review.
-
Clinical impact of microbiome in patients with decompensated cirrhosis.World J Gastroenterol. 2018 Sep 14;24(34):3813-3820. doi: 10.3748/wjg.v24.i34.3813. World J Gastroenterol. 2018. PMID: 30228776 Free PMC article.
-
Gut-Liver-Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies.Biomedicines. 2024 Jun 24;12(7):1398. doi: 10.3390/biomedicines12071398. Biomedicines. 2024. PMID: 39061972 Free PMC article. Review.
-
Gut microbiota of hepatitis B virus-infected patients in the immune-tolerant and immune-active phases and their implications in metabolite changes.World J Gastroenterol. 2022 Sep 21;28(35):5188-5202. doi: 10.3748/wjg.v28.i35.5188. World J Gastroenterol. 2022. PMID: 36188719 Free PMC article.
References
-
- Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 2014; 28: 753–770. - PubMed
-
- Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907–1917. - PubMed
-
- Kåhrström CT, Pariente N, Weiss U. Intestinal microbiota in health and disease. Nature 2016; 535: 47–47. - PubMed
-
- Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut 2016; 65: 2035–2044. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources